Xenetic Biosciences, Inc. (XBIO)
NASDAQ: XBIO · Real-Time Price · USD
3.900
-0.170 (-4.18%)
At close: Sep 11, 2026, 4:00 PM EDT
3.862
-0.038 (-0.98%)
After-hours: Sep 11, 2026, 7:30 PM EDT
Xenetic Biosciences Employees
Xenetic Biosciences had 2 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
2
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$1,630,389
Profits / Employee
-$1,237,547
Market Cap
9.14M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 2 | 0 | - | 2 | 0 |
| Dec 31, 2024 | 2 | -2 | -50.00% | 2 | 0 |
| Dec 31, 2023 | 4 | 0 | - | 4 | 0 |
| Dec 31, 2022 | 4 | 0 | - | 4 | 0 |
| Dec 31, 2021 | 4 | 0 | - | 4 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| CytoMed Therapeutics | 42 |
| Senti Biosciences Holdings | 39 |
| Imunon | 20 |
| Ensysce Biosciences | 10 |
| Aprea Therapeutics | 8 |
| CNS Pharmaceuticals | 8 |
| Traws Pharma | 7 |
| Alzamend Neuro | 6 |
XBIO News
- 5 weeks ago - Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform - Accesswire
- 5 weeks ago - Xenetic Biosciences Quarterly report: Q2 2026 - Filings
- 5 weeks ago - Xenetic Biosciences Earnings release: Q2 2026 - Filings
- 3 months ago - Xenetic partner PeriNess receives Israeli MOH approval for DNase I study - TheFly
- 3 months ago - Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma - Accesswire
- 3 months ago - Xenetic announces preclinical data on DNase I at ASCO - TheFly
- 3 months ago - Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival - Accesswire
- 3 months ago - Xenetic Biosciences Slides: Investor presentation - Filings